Gilead Sciences, Inc.GILD

Is GILD cheap right now? Every multiple below is scored against its own 10-year range, not a sector average.

$146.41+2.69 (+1.87%)24:00 UTC
NASDAQHealthcare

Company snapshot

Market Cap
$182B
Large-cap
+74%
2016 — today
10-Year Price
+90%
2016 — today
52-Week Range
$110.56$155.80
Current $146.41· 79%

Gilead Sciences discovers, develops, and commercializes innovative therapies for critical health needs globally. Its portfolio includes HIV treatments (Biktarvy, Genvoya, Descovy, Truvada), the COVID-19 antiviral Veklury, and liver disease medications (Epclusa, Harvoni, Vemlidy). It also addresses hematology, oncology, and cell therapy (Yescarta, Tecartus, Trodelvy), alongside treatments for pulmonary arterial hypertension and fungal infections. Gilead collaborates with partners like Merck and BMS to advance its pipeline.

Featured in rankings

Rankings recomputed after each US market close — see where GILD stands against peers.

Similar companies

Healthcare companies of comparable size to GILD
CompanyP/EDiv yield
ABTAbbott Laboratories33.12.4%
NVONovo Nordisk A/S10.74.1%
AMGNAmgen Inc.23.72.6%
PFEPfizer Inc.36.66.2%
TMOThermo Fisher Scientific Inc.33.00.3%
DHRDanaher Corporation36.10.7%
ISRGIntuitive Surgical, Inc.43.0
VRTXVertex Pharmaceuticals Incorporated30.2

Healthcare companies of comparable size — each one shown against its own 10-year range, not a sector average. Browse all stocks we cover.

Valuation in context

P/E ratio
-54.8
N/A
Not meaningful — company is unprofitable
Sector median 25.1below sector
P/B ratio
15.5
Near historic high
Near historic highs — last 10 years
Sector median 2.5above sector
EV / EBITDA
322.4
Near historic high
Near historic highs — last 10 years
Sector median 15.4above sector
Dividend Yield
2.2%
Near historic low
Near historic low — last 10 years
Sector median 1.7%above sector
FCF Yield
7.3%
Historically low
Historically low relative to the last 10 years
Sector median -10.1%above sector
Free · No credit card needed

Get alerted when GILD is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.